Orthocell Ltd (OCC) - Total Liabilities

Latest as of June 2025: AU$20.67 Million AUD ≈ $14.62 Million USD

Based on the latest financial reports, Orthocell Ltd (OCC) has total liabilities worth AU$20.67 Million AUD (≈ $14.62 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Orthocell Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Orthocell Ltd - Total Liabilities Trend (2010–2025)

This chart illustrates how Orthocell Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Orthocell Ltd total assets.

Orthocell Ltd Competitors by Total Liabilities

The table below lists competitors of Orthocell Ltd ranked by their total liabilities.

Company Country Total Liabilities
De Licacy Industrial Co Ltd
TW:1464
Taiwan NT$11.72 Billion
QINGCI GAMES INC. -00001
F:Z56
Germany €156.41 Million
Jalles Machado S/A
SA:JALL3
Brazil R$5.41 Billion
Ambra SA
WAR:AMB
Poland zł312.24 Million
COMMERCIAL SYN BAGS ORD (BSE)
NSE:COMSYN
India Rs1.53 Billion
VenueG Co. Ltd
KQ:019010
Korea ₩338.16 Billion
ISC Fresh Water Investment SOCIMI SA
MC:YISC
Spain €128.90 Million
West Wits Mining Ltd
AU:WWI
Australia AU$22.12 Million

Liability Composition Analysis (2010–2025)

This chart breaks down Orthocell Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Orthocell Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 4.97 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio 4.47 Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 1.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.59 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Orthocell Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Orthocell Ltd (2010–2025)

The table below shows the annual total liabilities of Orthocell Ltd from 2010 to 2025.

Year Total Liabilities Change
2025-06-30 AU$20.67 Million
≈ $14.62 Million
-6.40%
2024-06-30 AU$22.08 Million
≈ $15.62 Million
-5.86%
2023-06-30 AU$23.46 Million
≈ $16.60 Million
-16.20%
2022-06-30 AU$27.99 Million
≈ $19.81 Million
+1039.68%
2021-06-30 AU$2.46 Million
≈ $1.74 Million
+8.34%
2020-06-30 AU$2.27 Million
≈ $1.60 Million
-21.10%
2019-06-30 AU$2.87 Million
≈ $2.03 Million
+0.54%
2018-06-30 AU$2.86 Million
≈ $2.02 Million
+16.81%
2017-06-30 AU$2.45 Million
≈ $1.73 Million
+9.77%
2016-06-30 AU$2.23 Million
≈ $1.58 Million
+3.54%
2015-06-30 AU$2.15 Million
≈ $1.52 Million
-57.48%
2014-06-30 AU$5.06 Million
≈ $3.58 Million
+636.52%
2013-06-30 AU$687.24K
≈ $486.27K
+100.36%
2011-06-30 AU$343.00K
≈ $242.69K
+67.32%
2010-06-30 AU$205.00K
≈ $145.05K
--

About Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$132.46 Million
AU$187.20 Million AUD
Market Cap Rank
#18205 Global
#553 in Australia
Share Price
AU$0.69
Change (1 day)
-0.72%
52-Week Range
AU$0.69 - AU$1.53
All Time High
AU$1.75
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more